RTSN: Retension Pharmaceuticals, Inc. insider trading, 5% holders and institutional ownership
From public SEC filings: open-market insider purchases and sales (Form 4, last 180 days), holders of 5% or more (Schedules 13D and 13G) and institutional ownership (Form 13F). Insider and 5% data delayed 48 hours.
Insider trading
2 open-market buys totaling $370K and 0 sales totaling - in the last 180 days.
Insider buys
| Score | Ticker | Company | Insider | Role | Trade date | Value | Holding + | Cluster |
|---|---|---|---|---|---|---|---|---|
| 56 | RTSN | Retension Pharmaceuticals, Inc. | Keller Eric L. | CEO | 2026-10-13 | $250K | 5% | 2 insiders |
| 50 | RTSN | Retension Pharmaceuticals, Inc. | Berger Franklin M | Director | 2026-10-13 | $120K | new | 2 insiders |
Activist and 5% holders
| Filed | What | Holder | Stake | Change | Filing |
|---|---|---|---|---|---|
| 2026-10-16 | New 13G stake | The B Group, Inc. | 10.00% | SEC | |
| 2026-10-16 | New 13G stake | PVG ASSET MANAGEMENT CORP | 8.30% | SEC | |
| 2026-10-15 | New 13G stake | Laurence W. Lytton | 7.40% | SEC | |
| 2026-10-14 | New 13D stake | Eric Keller | 7.07% | SEC |
Get new insider and activist filings the morning after: daily alerts. Not investment advice.